Novartis Bets Big on RNA Technology to Target Parkinson’s Protein

In a major leap toward Parkinson’s treatment, Novartis has secured exclusive global rights to a new genetic therapy developed by Arrowhead Pharmaceuticals. The drug—called ARO-SNCA—aims to lower levels of alpha-synuclein, a protein that builds up in the brains of people with Parkinson’s. What’s the Deal? $200 million upfront: Novartis is putting serious money behind this — $200 million goes to Arrowhead as soon as the agreement closes. $2 billion more in milestones and royalties: If the therapy hits certain development or sales goals, Arrowhead could earn up to $2 billion in additional payments. Novartis takes over after preclinical: Arrowhead will manage early-stage development until the therapy is ready for clinical trial application. From then on, Novartis will lead development, manufacturing, and eventual commercialization. What Is ARO-SNCA? ARO-SNCA is an experimental therapy using RNA interference (RNAi)—a process that turns off problematic genes. In this case, the therapy uses small interfering RNAs (siRNAs) to reduce production of alpha-synuclein in the brain. Here’s how it works: Targeted delivery: Arrowhead’s TRiM™ platform allows delivery of the siRNA via injection, with the ability to reach deep brain structures. Why alpha-synuclein matters: This misfolded protein forms toxic clumps in Parkinson’s, and targeting it directly might slow or stop disease progression. A second chance for Novartis: Previously, Novartis had been working on a small-molecule inhibitor targeting alpha-synuclein, but that approach failed in mid-stage testing. Now they’re backing a fresh, RNA-based strategy. So Why This Matters A bold move into RNA: Novartis already has experience with RNA therapies—like Leqvio, used for high cholesterol. This partnership shows increased confidence in RNA as a real-world therapeutic approach for brain disease. Preclinical roots: ARO-SNCA is still in early testing, but the pharmacological groundwork is solid, and Novartis clearly sees promise that could make this a potential breakthrough for Parkinson’s. Wider potential: The agreement also allows for development of other therapies using the same TRiM platform, giving Novartis access to more opportunities down the line.